Edition:
United States

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

2.05USD
12:55pm EST
Change (% chg)

$0.01 (+0.49%)
Prev Close
$2.04
Open
$2.06
Day's High
$2.20
Day's Low
$2.04
Volume
365,818
Avg. Vol
266,019
52-wk High
$3.14
52-wk Low
$1.75

Chart for

About

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry,... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $324.83
Shares Outstanding(Mil.): 159.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 207.59 16.63
EPS (TTM): -- -- --
ROI: -- -11.19 33.78
ROE: -- -33.91 17.31

BRIEF-Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019

* GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​ Source text (http://bit.ly/2COKF0K) Further company coverage:

Jan 08 2018

BRIEF-Geron Corp Q3 loss per share $0.04

* Geron Corporation reports third quarter 2017 financial results

Nov 01 2017

BRIEF-Geron announces fast track designation grant for imetelstat

* Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes

Oct 31 2017

BRIEF-Geron Q2 loss per share $0.04

* Geron Corporation reports second quarter 2017 financial results

Aug 09 2017

BRIEF-Geron provides updates to imetelstat clinical development

* Expects imbark protocol-specified primary analysis to begin no later than q3 of 2018 Source text for Eikon: Further company coverage:

Jul 31 2017

Competitors

Earnings vs. Estimates